Stocks and Investing
Stocks and Investing
Thu, April 22, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Wed, April 21, 2021
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Gena Wang Maintained (VRTX) at Buy and Held Target at $302 on, Apr 21st, 2021
Gena Wang of Barclays, Maintained "Vertex Pharmaceuticals Incorporated" (VRTX) at Buy and Held Target at $302 on, Apr 21st, 2021.
Gena has made no other calls on VRTX in the last 4 months.
There are 7 other peers that have a rating on VRTX. Out of the 7 peers that are also analyzing VRTX, 2 agree with Gena's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Matthew Harrison of "Morgan Stanley" Maintained at Hold with Increased Target to $253 on, Monday, April 19th, 2021
- Geoffrey Porges of "SVB Leerink" Maintained at Hold with Decreased Target to $250 on, Tuesday, February 2nd, 2021
These are the ratings of the 5 analyists that currently disagree with Gena
- Brian Skorney of "Baird" Maintained at Buy and Held Target at $252 on, Tuesday, April 20th, 2021
- Brian Abrahams of "RBC Capital" Maintained at Buy and Held Target at $265 on, Friday, April 16th, 2021
- Do Kim of "BMO Capital" Maintained at Buy with Decreased Target to $284 on, Tuesday, February 2nd, 2021
- Edward Tenthoff of "Piper Sandler" Maintained at Buy with Increased Target to $347 on, Tuesday, February 2nd, 2021
- Evan Seigerman of "Credit Suisse" Maintained at Buy with Decreased Target to $280 on, Tuesday, February 2nd, 2021
Contributing Sources